- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00827892
Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage (SHRINC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Intracerebral hemorrhage (ICH) remains a devastating disease and current treatment options lag far behind those for ischemic stroke. Current treatment efforts for ICH are targeted towards the primary brain injury caused by the hemorrhage and growth of the hematoma. This research targets the secondary injury caused by the persistence of toxic blood degradation products in the brain parenchyma.
Based on preclinical work in our lab, the peroxisome proliferator activated receptor-gamma (PPARγ), a member of the nuclear receptor superfamily, represents a possible target for the treatment of ICH aimed at promoting hematoma absorption, limiting the pro-inflammatory response, and protecting salvageable tissue from the damage produced by the persistence of toxic blood degradation products.
Our primary specific aim is to assess the safety of the PPARγ agonist, pioglitazone (PIO) in increasing doses for 3 days, when administered to patients with ICH within 24 hrs of symptom onset. Secondarily, we aim to determine the duration of treatment of PIO for hematoma/edema resolution in ICH. Lastly, we aim to determine whether speed of hematoma/edema resolution in ICH represents a radiographic biological marker of activity which can be correlated with clinical outcome and treatment effect of PIO. The ultimate purpose is to provide baseline data on an aspect of ICH which has not been previously targeted for treatment in an effort to develop a safe and effective treatment strategy that may be practical and applicable for both specialized stroke centers and community hospitals.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Memorial Hermann Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age 18-80 years
- clinical presentation of spontaneous ICH
- CT scan compatible with spontaneous ICH
- Time to PIO treatment ≤ 24 hours from symptom onset
- GCS ≥ 6 on initial presentation OR improvement to a GCS ≥ 6 within the time frame for enrollment
- Hematoma volume ≥ 5cc on initial head CT.
Exclusion Criteria:
- Participation in another investigational trial in the previous 30 days
- Patient will undergo surgical evacuation of ICH (ventriculostomy does NOT exclude patient)
Inability to undergo neuroimaging with MRI (e.g. pacer, recent stent, inability to lie flat)
a. If patient has mild claustrophobia or agitation amenable to mild sedation (1-2mg lorazepam IV or 5-10mg diazepam PO), he or she may be considered for enrollment. If, however, the patient has severe claustrophobia or agitation, he or she should not be considered for enrollment.
- GCS < 6
- Baseline mRS ≥ 3
- Primary intraventricular hemorrhage
- ICH due to coagulopathy (PT > 15 sec or INR > 1.3, PTT > 36) or trauma
- History of intolerance or allergy to any TZD
- Thrombocytopenia: platelet count < 100,000
- Clinically significant hepatic disease as demonstrated by history, clinical exam (ascites, varices), or laboratory findings (LFTs ≥ 2x normal, coagulopathy as described above)
Co-morbid conditions, which in the opinion of the investigator, are likely to complicate therapy including but not limited to:
- A history of NYHA class II, III, or IV CHF
- clinically significant arrhythmia
- end stage AIDS
- Pregnancy as determined by a urine pregnancy test
- Severe anemia at presentation: hemoglobin < 10 g/dL or hematocrit < 30%
- Malignancy (history of or active)
- Patient unlikely, in the investigator's opinion, to complete the study and return for follow-up visits for any reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI
Other Names:
|
Placebo Comparator: 2
|
Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary measure of safety will be mortality at discharge.
Time Frame: At hospital discharge or Day 14, whichever occurs first.
|
At hospital discharge or Day 14, whichever occurs first.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary measures of safety will include mortality at 3 months and 6 months, symptomatic cerebral edema during hospitalization, clinically significant congestive heart failure, edema, hypoglycemia, anemia, and hepatotoxicity.
Time Frame: 3 months, 6 months, and during hospitalization
|
3 months, 6 months, and during hospitalization
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nicole R Gonzales, MD, University of Texas Medical School-Houston
Publications and helpful links
General Publications
- Zhao X, Sun G, Zhang J, Strong R, Song W, Gonzales N, Grotta JC, Aronowski J. Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor gamma in microglia/macrophages. Ann Neurol. 2007 Apr;61(4):352-62. doi: 10.1002/ana.21097.
- Zhao X, Grotta J, Gonzales N, Aronowski J. Hematoma resolution as a therapeutic target: the role of microglia/macrophages. Stroke. 2009 Mar;40(3 Suppl):S92-4. doi: 10.1161/STROKEAHA.108.533158. Epub 2008 Dec 8.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-08-0410
- P50 NS044227-5
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracerebral Hemorrhage
-
Wake Forest University Health SciencesActive, not recruitingStroke Hemorrhagic | Intracerebral Hemorrhage | Cerebral Edema | Intracerebral Hemorrhage, Hypertensive | Intracerebral Hemorrhage IntraparenchymalUnited States
-
Beijing Tiantan HospitalBeijing Friendship Hospital; RenJi Hospital; Qilu Hospital of Shandong University and other collaboratorsRecruitingSpontaneous Intracerebral HemorrhageChina
-
University Hospital, Basel, SwitzerlandSwiss Heart FoundationActive, not recruitingIntracerebral Hemorrhage (ICH)Switzerland
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
AegisCN LLCCompletedIntracerebral Hemorrhage (ICH)United States
-
Tongji HospitalUnknown
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
CellMed AG, a subsidiary of BTG plc.TerminatedIntracerebral Hemorrhage (ICH)Germany
-
Tang-Du HospitalRecruitingIntracerebral Hemorrhage;Circulating ExosomesChina
Clinical Trials on Pioglitazone
-
Dong-A ST Co., Ltd.CompletedType 2 DiabetesKorea, Republic of
-
Solvay PharmaceuticalsCompletedType 2 Diabetes MellitusUnited Kingdom
-
Emory UniversityCompletedDiabetic Ketoacidosis | Ketosis Prone Diabetes | Severe HyperglycemiaUnited States
-
University at BuffaloTakeda Pharmaceuticals North America, Inc.Completed
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceNot yet recruitingANCA Associated Vasculitis | Rapidly Progressive Glomerulonephritis | Crescentic Glomerulonephritis
-
National Cancer Institute (NCI)CompletedHead and Neck Cancer | Oral LeukoplakiaUnited States
-
University of Campinas, BrazilRecruitingMyocardial Reperfusion InjuryBrazil
-
West Virginia UniversityRecruitingBreast Cancer | Muscle FatigueUnited States
-
University of Texas Southwestern Medical CenterNational Institutes of Health (NIH)Completed
-
University of Texas Southwestern Medical CenterRecruitingNephrolithiasis, Uric AcidUnited States